President Donald Trump is set to sign an executive order opening the door to federal funding for ibogaine research for PTSD. It marks a notable shift in how the United States approaches psychedelic substances in a medical context.

CBS News first reported the move. It signals the administration’s interest in whether ibogaine, a naturally occurring compound from a shrub native to West Africa, could help veterans suffering from post-traumatic stress disorder, traumatic brain injuries, and addiction.

What Is Ibogaine and Why Does Ibogaine Research for PTSD Matter?

Countries including Mexico and Canada already use ibogaine to treat depression, anxiety, opioid dependence, and PTSD. Despite growing international interest, the drug remains a Schedule I controlled substance in the United States. The DEA places it alongside heroin and ecstasy. Schedule I substances carry “no currently accepted medical use and a high potential for abuse.”

That legal status has left Americans with few options. Many travel to unregulated clinics in Mexico or the Caribbean to access treatment. Those clinics operate with no standardised heart screening, no required monitoring, and no obligation to report adverse events.

The executive order will not reclassify ibogaine for medical use at this stage. Instead, the administration wants to fund further scientific study, with a particular focus on veterans.

Veterans Drive the Push for Ibogaine Research for PTSD

Veterans’ advocacy groups and researchers have fuelled much of the momentum here. They argue that existing treatments fail too many people. A Stanford Medicine study published last July followed 30 veterans who took ibogaine alongside intravenous magnesium. Researchers used the magnesium to protect the heart. The study recorded significant reductions in PTSD symptoms, anxiety, and depression, with no serious cardiac events during the trial.

Researchers are careful to note the limitations. Only 30 participants took part, and the study had no placebo group. The findings are promising, but far too early to draw firm conclusions about safety or effectiveness.

The numbers from broader reviews are sobering. A 2023 analysis of 24 studies covering 705 people found ibogaine reduced withdrawal symptoms and cravings. But it flagged cardiac toxicity and death risk as “worrying.” At least 27 people have died after taking ibogaine, according to that review.

CBS News’ “60 Minutes” drew wider public attention to the issue last year. The programme followed nine American veterans who travelled to a village near Puerto Vallarta, Mexico, for a week-long psychedelic retreat to address trauma and intrusive memories.

Texas Leads State Efforts on Psychedelic Treatment for PTSD

Texas moved before the federal government did. Governor Greg Abbott signed a bill last year approving 50 million dollars for ibogaine research. That makes Texas one of the most active states in pursuing psychedelic treatment for PTSD at an institutional level.

The Trump administration openly admits the science is early. One official put it plainly: the goal is to find out whether ibogaine is “snake oil” or a legitimate treatment.

The Science Still Has a Long Way to Go

Small observational studies and open-label trials make up most of the current evidence base. Researchers have completed only one double-blind, placebo-controlled randomised clinical trial to date. Larger, more rigorous trials are only now getting under way.

Cardiac risk sits at the top of the concern list. Ibogaine can trigger dangerous heart rhythm disturbances. Some of these have been fatal. Scientists have looked at whether intravenous magnesium can reduce this risk, but the evidence remains thin.

Any path to regulatory approval for ibogaine would require full clinical trials with robust safety monitoring and transparent reporting of adverse outcomes.

What the Executive Order Could Mean in Practice

The federal government had not finalised how it would support ibogaine research for PTSD at the time of reporting. Strategies under discussion include directing federal funding toward clinical trials and building frameworks that let researchers study the substance more easily on US soil.

The administration’s approach reflects a cautious but growing recognition that some psychedelic compounds may hold real therapeutic value. Experts consistently warn, though, that enthusiasm must not run ahead of the evidence, especially given the serious risks that come with unsupervised use.

Anyone considering ibogaine treatment should know that accessing it outside a properly supervised research setting carries significant and unquantified risks. Recovery stories exist, but so do documented cases of serious harm and death.

Source: dbrecoveryresources